Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6535
    +0.0012 (+0.18%)
     
  • OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD

    2,349.60
    +7.10 (+0.30%)
     
  • Bitcoin AUD

    97,960.84
    -1,046.33 (-1.06%)
     
  • CMC Crypto 200

    1,383.71
    -12.82 (-0.92%)
     
  • AUD/EUR

    0.6108
    +0.0035 (+0.57%)
     
  • AUD/NZD

    1.0994
    +0.0037 (+0.33%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,718.30
    +287.79 (+1.65%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,239.66
    +153.86 (+0.40%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Pfizer COVID vaccine safe for younger kids -data

Welcome news for anxious parents eager to have their kids vaccinated against COVID-19…

Pfizer and BioNTech said Monday that a lower dose of their COVID-19 vaccine induces a robust immune response in 5 to 11 year olds, and they plan to ask for authorization – from the FDA and other regulators - as soon as possible.

Clinical trials showed the Pfizer vaccine was well-tolerated, and generated an immune response in 5 to 11 year-olds, as it had in the older age range. The dose for younger kids was one-third the size.

The companies said the safety profile was also generally comparable.

Top U.S. health officials believe regulators could make a decision on whether a lower dose shot is safe and effective for this age group within three weeks of the companies submitting a request for authorization, according to sources.

ADVERTISEMENT

A rapid authorization in the U.S. could help stem a potential surge of coronavirus cases in the fall, with schools open across the country.

Pediatric cases have risen sharply in recent months - as have hospitalizations - due to the highly contagious Delta variant.